UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): November 2, 2007

ZIOPHARM Oncology, Inc.
(Exact name of registrant as specified in its charter)

Delaware	0-32353	84-1475642
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1180 Avenue of the Americas, 19th Floor
New York, NY 10036
(Address of principal executive offices) (Zip Code)

(646) 214-0700
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On November 2, 2007 and November 5, 2007, ZIOPHARM Oncology, Inc. issued the press releases attached hereto as Exhibits 99.1 and 99.2, respectively, which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated November 2, 2007.

99.2 Press Release dated November 5, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.:
(Registrant)

Date: November 5, 2007

By: /s/ Richard E. Bagley
Richard E. Bagley, *President, Chief Operating Officer and Chief Financial Officer*

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated November 2, 2007.
99.2	Press Release dated November 5, 2007.

Exhibit 99.1

ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology Reports Third Quarter Results

NEW YORK (November 02, 2007) - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs, today reported financial results for the three and nine months ended September 30, 2007.

The Company reported a net loss for the third quarter of 2007 of $7.3 million, or $(0.35) per share, compared with a net loss for the third quarter of 2006 of $3.5 million, or $(0.23) per share. Total operating expenses for the quarter were $7.9 million, compared with $3.9 million for the same quarter in the prior year. The increase was primarily due to higher expenses associated with the continued clinical development of ZIO-101 (darinaparsin), ZIO-201 (IPM) and ZIO-301 (indibulin). Cash used in operations during the third quarter 2007 was $5.6 million, compared with $2.6 million used in the third quarter 2006.

For the first nine months of 2007 the Company reported a net loss of $18.9 million, or $(0.94) per share, compared with a net loss of $12.0 million, or $(1.03) per share for the same period of 2006. Total operating expenses for the nine months ended September 30, 2007 were $20.5 million, compared with $12.9 million for the comparable prior-year period. Cash used in operations for the first nine months of 2007 was $15.8 million, compared with $8.5 million used in the same period of 2006. As of September 30, 2007 ZIOPHARM had cash and cash equivalents of $40.9 million, compared with $26.9 million as of December 31, 2006.

Highlights since the beginning of the third quarter 2007 included:

- Presentation of positive phase II ZIO-201 interim sarcoma data at the European Society for Medical Oncology (ESMO), which demonstrated clinical benefit and showed ZIO-201 to be well tolerated at the phase II dose with no significant bone marrow suppression, alopecia (hair loss) or neurotoxicity reported;
- Initiation of patient dosing in a U.S. phase I trial of oral darinaparsin (ZIO-101) to treat solid tumors;
- Allowance of patent claims for darinaparsin (ZIO-101), which cover all oral formulations of organic arsenic;
- Presentation of phase II clinical data for ZIO-201 (IPM) at the 14th Annual European Cancer Conference (ECCO), which demonstrated a clinically beneficial response and tolerability with adverse events primarily mild to moderate;
- Presentation of positive clinical data of darinaparsin (ZIO-101) at the 14th Annual European Cancer Conference (ECCO), which showed clinical activity in patients with advanced hematological malignancies and, importantly, showed darinaparsin to be well tolerated, particularly with regard to cardiac toxicity, and adverse events were mild to moderate in severity.

Jonathan Lewis, MD, PhD, Chief Executive Officer of ZIOPHARM, commented, “In the third quarter, we accomplished significant clinical progress with all three of our product candidates and remain encouraged by the flow of positive data that have been presented at leading medical and scientific meetings. We were especially pleased with the interim results from the ongoing phase II trial with ZIO-201 in patients with advanced sarcoma.”

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies, and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Statements

This news release contains forward-looking statements based on current expectations, forecasts and assumptions that are subject to risks and uncertainties that could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or that such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this news release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law. For further risk factors see the Company's 10-KSB filed with the SEC.

ZIOP-G

CONTACTS:

Investors:
ZIOPHARM Oncology, Inc.
Suzanne McKenna, Investor Relations
646-214-0703
smckenna@ziopharm.com

Argot Partners
Andrea Rabney, 212-600-1902
andrea@argotpartners.com

ZIOPHARM Oncology, Inc.

ZIOPHARM Presents Positive Phase II Data for ZIO-201 in Soft Tissue and Bone Sarcomas at Connective Tissue Oncology Society (CTOS) Annual Meeting

Data Support Development of Randomized Phase III Study for 2008

NEW YORK, New York, November 5, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of positive data from an ongoing Phase II study of ZIO-201 used in soft tissue and bone sarcomas at the Connective Tissue Oncology Society (CTOS) Annual Meeting which was held in Seattle, Washington from November 1-3, 2007.

The Phase I/II study in advanced/unresectable soft tissue and bone sarcomas, including a diverse range of histological subtypes, has been fully enrolled at 54 patients, with 50 in Phase II as reported on at CTOS. Of 44 evaluable patients, 48% had stable disease or better with a median progression free survival of 10 weeks. Among the 11 patients enrolled in the study who had not previously received the chemotherapy agent ifosfamide (IFOS), stable disease or better was reported in 64% of patients and the median progression free survival has not yet been reached.

The most common toxicities were mild to moderate and gastrointestinal or renal related, with no reports of central nervous system or bladder toxicities and no significant bone marrow suppression or alopecia. Data from the study support the Company's plans for the development and initiation of a randomized Phase III study of ZIO-201 in 2008.

"Progression free survival rates reported in this study compare favorably to rates reported for historical controls with fewer serious toxicities and a convenient dosing schedule," stated Rashmi Chugh, MD, Principal Investigator of the study and faculty at the University of Michigan. "These data are interesting, particularly in heavily pre-treated patients, and support further evaluation of ZIO-201."

"Bone and soft tissue sarcomas are less common cancers and, unfortunately, patients suffering from advanced forms of the diseases have poor prognoses and no FDA approved treatment options," stated Jonathan Lewis, MD, PhD, Chief Executive Officer of ZIOPHARM Oncology. "In addition, current treatments, particularly ifosfamide, carry with them a significant level of toxicity that can result in debilitating side effects. Based on data from this study, we are optimistic about ZIO-201 as a potential treatment option for sarcomas and will work closely with the medical and regulatory communities as we develop our Phase III trial approach."

The trial was a 2-stage Simon design, with ZIO-201 administered daily for 3 consecutive days every 3 weeks for up to 6 cycles or until disease progression or unacceptable toxicity occurs. All evaluable patients had baseline ECOG scores of less than 2 and the median number of prior chemotherapies was 5. 76% of patients had previously received IFOS.

About ZIO-201

ZIO-201, the active moiety of ifosfamide (IFOS), is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking resulting in cell death. ZIO-201 is equal to or more active than IFOS in diverse cancer models. Unlike IFOS, which is a pro-drug, ZIO-201 is directly active against cancer cells. Also, unlike IFOS, ZIO-201 is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities. ZIO-201 continues in a Phase II trial in advanced sarcoma. Trials in ovarian and pediatric cancers are in the planning stage. An oral form of ZIO-201 is in advanced preclinical development.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

CONTACT:

ZIOPHARM Oncology, Inc.
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com

Argot Partners
Andrea Rabney, 212-600-1902
andrea@argotpartners.com